These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 3145994)

  • 1. [Improvement in anti-hemophilic preparations and its problems. 2. Inadequacy of the heat treatment of factor concentrates on the inactivation of non-A, non-B hepatitis virus].
    Inagaki M; Osano M
    Rinsho Ketsueki; 1988 May; 29(5):635-9. PubMed ID: 3145994
    [No Abstract]   [Full Text] [Related]  

  • 2. [Improvement in anti-hemophilic preparations and arts problems. 1. Heat-treated concentrates].
    Ikematsu S; Yorifuji H; Arai M; Fukutake K
    Rinsho Ketsueki; 1988 May; 29(5):628-34. PubMed ID: 3145993
    [No Abstract]   [Full Text] [Related]  

  • 3. Non-A, non-B hepatitis associated with a factor IX complex infused during cardiovascular surgery--Arizona.
    Centers for Disease Control (CDC)
    MMWR Morb Mortal Wkly Rep; 1986 Jun; 35(24):391-4, 399. PubMed ID: 3086697
    [No Abstract]   [Full Text] [Related]  

  • 4. Serological evidence that dry heating of clotting factor concentrates prevents transmission of non-A, non-B hepatitis.
    Skidmore SJ; Pasi KJ; Mawson SJ; Williams MD; Hill FG
    J Med Virol; 1990 Jan; 30(1):50-2. PubMed ID: 2106006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatitis C and pasteurised factor VIII and IX concentrates.
    Klarmann D; Kreuz W; Auerswald G; Auberger K; Rabenau H; Gürtler L; Roggendorf M
    Thromb Haemost; 1995 Apr; 73(4):736-7. PubMed ID: 7495095
    [No Abstract]   [Full Text] [Related]  

  • 6. Improvement of virus safety of an antihemophilc factor IX by virus filtration process.
    Kim IS; Choi YW; Kang Y; Sung HM; Sohn KW; Kim YS
    J Microbiol Biotechnol; 2008 Jul; 18(7):1317-25. PubMed ID: 18667862
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Improvement in anti-hemophilic preparations and its problems. 6. Function analysis of human plasma proteins passed through the microporous regenerated cellulose membrane (BMM) hollow fiber].
    Okuyama K; Fukushima Y; Miura Y; Honma R; Manabe S; Ishikawa G; Satani M; Komuro K
    Rinsho Ketsueki; 1988 May; 29(5):662-5. PubMed ID: 3216492
    [No Abstract]   [Full Text] [Related]  

  • 8. Revision of the protocol recommended for studies of safety from hepatitis of clotting factor concentrates. International Society for Thrombosis and Hemostasis.
    Mannucci PM; Colombo M
    Thromb Haemost; 1989 Jun; 61(3):532-4. PubMed ID: 2508261
    [No Abstract]   [Full Text] [Related]  

  • 9. Effect of dry-heating of coagulation factor concentrates at 80 degrees C for 72 hours on transmission of non-A, non-B hepatitis. Study Group of the UK Haemophilia Centre Directors on Surveillance of Virus Transmission by Concentrates.
    Lancet; 1988 Oct; 2(8615):814-6. PubMed ID: 2902265
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Inactivation of hepatitis non-A, non-B virus in intravenous immunoglobulins by beta-propiolactone].
    Dichtelmüller H; Stephan W; Prince AM; Brotman B
    Beitr Infusionsther; 1988; 21():202-4. PubMed ID: 2462976
    [No Abstract]   [Full Text] [Related]  

  • 11. Removal and inactivation of enveloped and non-enveloped viruses during the purification of a high-purity factor IX by metal chelate affinity chromatography.
    Roberts PL; Walker CP; Feldman PA
    Vox Sang; 1994; 67 Suppl 1():69-71. PubMed ID: 8091741
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heat treatment at 100 degrees C of factor VIII and IX coagulation factor concentrates.
    Teh LC; Woodfield DG
    Med J Aust; 1993 Sep; 159(5):355-6. PubMed ID: 8361441
    [No Abstract]   [Full Text] [Related]  

  • 13. [Transmission of hepatitis C by factor concentrates].
    Aguilar C; Lucía JF
    Sangre (Barc); 1996 Apr; 41(2):160-1. PubMed ID: 9045360
    [No Abstract]   [Full Text] [Related]  

  • 14. Inactivation and clearance of viruses during the manufacture of high purity factor IX.
    Johnston A; Macgregor A; Borovec S; Hattarki M; Stuckly K; Anderson D; Goss NH; Oates A; Uren E
    Biologicals; 2000 Sep; 28(3):129-36. PubMed ID: 10964439
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunoprophylaxis of non-B hepatitis (hepatitis A and non-A non-B hepatitis).
    Spector R
    J Iowa Med Soc; 1982 Mar; 72(3):112-3, 118. PubMed ID: 6802909
    [No Abstract]   [Full Text] [Related]  

  • 16. Dry-heat treatment process for enhancing viral safety of an antihemophilic factor VIII concentrate prepared from human plasma.
    Kim IS; Choi YW; Kang Y; Sung HM; Shin JS
    J Microbiol Biotechnol; 2008 May; 18(5):997-1003. PubMed ID: 18633304
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Virucidal treatment of clotting factor concentrates.
    Mannucci PM; Colombo M
    Lancet; 1988 Oct; 2(8614):782-5. PubMed ID: 2901620
    [No Abstract]   [Full Text] [Related]  

  • 18. Inactivation of HTLV-III/LAV, hepatitis B and non-A/non-B viruses by pasteurization in human plasma protein preparations.
    Mauler R; Merkle W; Hilfenhaus J
    Dev Biol Stand; 1987; 67():337-51. PubMed ID: 3111911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inactivation of hepatitis B and non-A, non-B viruses by combined use of Tween 80, beta-propiolactone, and ultraviolet irradiation.
    Prince AM; Stephan W; Kotitschke R; Brotman B
    Thromb Haemost; 1983 Aug; 50(2):534-6. PubMed ID: 6415846
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preparation and heat-treatment of factor-IX-concentrates.
    Stampe D; Wieland B; Köhle A
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1988; 115(4):523-7. PubMed ID: 2465966
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.